Drug Discovery for Diabetic Nephropathy: Trying the Leap From Mouse to Man

Seminars in Nephrology

Volumn 32, Issue 5, 2012, Pages 445-451

  Breyer, Matthew D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

creatinine; hypertension; Kidney; mouse; proteinuria

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; AVOSENTAN; BARDOXOLONE; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; INULIN; PARICALCITOL; PIRFENIDONE; PYRIDOXAMINE; SPIRONOLACTONE; SULODEXIDE;

ACCURACY; ALBUMINURIA; ARTICLE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; FIBROSING ALVEOLITIS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INULIN CLEARANCE; KIDNEY FAILURE; LOW DRUG DOSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG DISCOVERY; HUMANS; MICE;

EID: 84867373435     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.07.007     Document Type: Article

References (70)

1. Foley R.N., Collins A.J. The growing economic burden of diabetic kidney disease. Curr Diab Rep 2009, 9:460-465.
2. Gilbertson D.T., Liu J., Xue J.L., Louis T.A., Solid C.A., Ebben J.P., et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005, 16:3736-3741.
3. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
4. de Zeeuw D., Agarwal R., Amdahl M., Audhya P., Coyne D., Garimella T., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
5. Levey A.S., Cattran D., Friedman A., Miller W.G., Sedor J., Tuttle K., et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009, 54:205-226.
6. de Zeeuw D., Parekh R., Soman S. CKD treatment: time to alter the focus to albuminuria?. Adv Chronic Kidney Dis 2011, 18:222-223.
7. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
8. Logan B.R. Optimal two-stage randomized phase II clinical trials. Clinical Trials 2005, 2:5-12.
9. Eijkelkamp W.B., Zhang Z., Remuzzi G., Parving H.H., Cooper M.E., Keane W.F., et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007, 18:1540-1546.
10. Yokoyama H., Kanno S., Takahashi S., Yamada D., Honjo J., Saito K., et al. Risks for glomerular filtration rate decline in association with progression of albuminuria in type 2 diabetes. Nephrol Dial Transplant 2011, 26:2924-2930.
11. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921-927.
12. Heerspink H.J. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway. Adv Chronic Kidney Dis 2011, 18:290-299.
13. Kohan D.E., Pritchett Y., Molitch M., Wen S., Garimella T., Audhya P., et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011, 22:763-772.
14. Wenzel R.R., Littke T., Kuranoff S., Jurgens C., Bruck H., Ritz E., et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009, 20:655-664.
15. Mehdi U.F., Adams-Huet B., Raskin P., Vega G.L., Toto R.D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650.
16. Heerspink H.L., Greene T., Lewis J.B., Raz I., Rohde R.D., Hunsicker L.G., et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2008, 23:1946-1954.
17. Lewis E.J., Lewis J.B., Greene T., Hunsicker L.G., Berl T., Pohl M.A., et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis 2011, 58:729-736.
18. Mann J.F., Green D., Jamerson K., Ruilope L.M., Kuranoff S.J., Littke T., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010, 21:527-535.
19. Sharma K., Ix J.H., Mathew A.V., Cho M., Pflueger A., Dunn S.R., et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011, 22:1144-1151.
20. Richeldi L., Yasothan U., Kirkpatrick P. Pirfenidone. Nat Rev Drug Discov 2011, 10:489-490.
21. Levin A., Beaulieu M.C. Trials and tribulations of new agents, novel biomarkers, and retarding renal progression. J Am Soc Nephrol 2011, 22:992-993.
22. Pergola P.E., Raskin P., Toto R.D., Meyer C.J., Huff J.W., Grossman E.B., et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011, 365:327-336.
23. Rogacev K.S., Bittenbring J.T., Fliser D. Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med 2011, 365:1745-1746. author reply, 1746-7.
24. Upadhyay A., Sarnak M.J., Levey A.S. Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med 2011, 365:1746. author reply, 1746-7.
25. Dinkova-Kostova A.T., Liby K.T., Stephenson K.K., Holtzclaw W.D., Gao X., Suh N., et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005, 102:4584-4589.
26. Pergola P.E., Krauth M., Huff J.W., Ferguson D.A., Ruiz S., Meyer C.J., et al. Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol 2011, 33:469-476.
27. Wu Q.Q., Wang Y., Senitko M., Meyer C., Wigley W.C., Ferguson D.A., et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1. Am J Physiol Renal Physiol 2011, 300:F1180-F1192.
28. Brosius F.C., Alpers C.E., Bottinger E.P., Breyer M.D., Coffman T.M., Gurley S.B., et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009, 20:2503-2512.
29. Kohan D.E. Progress in gene targeting: using mutant mice to study renal function and disease. Kidney Int 2008, 74:427-437.
30. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
31. Cheng H., Fan X., Moeckel G.W., Harris R.C. Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro) renin receptor expression. J Am Soc Nephrol 2011, 22:1240-1251.
32. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015-8020.
33. Berthier C.C., Zhang H., Schin M., Henger A., Nelson R.G., Yee B., et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009, 58:469-477.
34. Yang H., Bell T.A., Churchill G.A., Pardo-Manuel de Villena F. On the subspecific origin of the laboratory mouse. Nat Genet 2007, 39:1100-1107.
35. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
36. Finne P., Reunanen A., Stenman S., Groop P.-H., Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005, 294:1782-1787.
37. Iyengar S.K., Abboud H.E., Goddard K.A., Saad M.F., Adler S.G., Arar N.H., et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes 2007, 56:1577-1585.
38. Rogus J.J., Poznik G.D., Pezzolesi M.G., Smiles A.M., Dunn J., Walker W., et al. High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach. Diabetes 2008, 57:2519-2526.
39. Breyer M.D., Bottinger E., Brosius F.C., Coffman T.M., Harris R.C., Heilig C.W., et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005, 16:27-45.
40. Gurley S.B., Mach C.L., Stegbauer J., Yang J., Snow K.P., Hu A., et al. Influence of genetic background on albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice. Am J Physiol Renal Physiol 2010, 298:F788-F795.
41. Qi Z., Fujita H., Jin J., Davis L.S., Wang Y., Fogo A.B., et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005, 54:2628-2637.
42. Kimmelstiel P., Wilson C. Intercapillary lesions in the glomeruli of kidney. Am J Pathol 1936, 12:83-97.
43. Wilson J.L., Root H.F., Marble A. Diabetic nephropathy; a clinical syndrome. N Engl J Med 1951, 245:513-517.
44. Hudkins K.L., Pichaiwong W., Wietecha T., Kowalewska J., Banas M.C., Spencer M.W., et al. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 2010, 21:1533-1542.
45. Bohle A., Wehrmann M., Bogenschutz O., Batz C., Muller C.A., Muller G.A. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991, 187:251-259.
46. White K.E., Bilous R.W. Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol 2000, 11:1667-1673.
47. Zatz R., Dunn B.R., Meyer T.W., Anderson S., Rennke H.G., Brenner B.M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925-1930.
48. Szoka P.R., Paigen K. Regulation of mouse major urinary protein production by the Mup-A gene. Genetics 1978, 90:597-612.
49. Sluiter W., Oomens L.W., Brand A., Van Furth R. Determination of blood volume in the mouse with 51chromium-labelled erythrocytes. J Immunol Methods 1984, 73:221-225.
50. Yuen P.S., Dunn S.R., Miyaji T., Yasuda H., Sharma K., Star R.A. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004, 286:F1116-F1119.
51. Takahashi N., Boysen G., Li F., Li Y., Swenberg J.A. Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 2007, 71:266-271.
52. Dunn S.R., Qi Z., Bottinger E.P., Breyer M.D., Sharma K. Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 2004, 65:1959-1967.
53. Keppler A., Gretz N., Schmidt R., Kloetzer H.M., Groene H.J., Lelongt B., et al. Plasma creatinine determination in mice and rats: an enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int 2007, 71:74-78.
54. Kemperman F.A., Silberbusch J., Slaats E.H., van Zanten A.P., Weber J.A., Krediet R.T., et al. Glomerular filtration rate estimation from plasma creatinine after inhibition of tubular secretion: relevance of the creatinine assay. Nephrol Dial Transplant 1999, 14:1247-1251.
55. Kemperman F.A., Silberbusch J., Slaats E.H., Prins A.M., Weber J.A., Krediet R.T., et al. Estimation of the glomerular filtration rate in NIDDM patients from plasma creatinine concentration after cimetidine administration. Diabetes Care 1998, 21:216-220.
56. Eisner C., Faulhaber-Walter R., Wang Y., Leelahavanichkul A., Yuen P.S., Mizel D., et al. Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int 2010, 77:519-526.
57. Abrahamson M., Grubb A., Olafsson I., Lundwall A. Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine proteinase inhibitor cystatin C. FEBS Lett 1987, 216:229-233.
58. Stevens L.A., Coresh J., Schmid C.H., Feldman H.I., Froissart M., Kusek J., et al. Estimating GFR using serum cystatin c alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008, 51:395-406.
59. Hakansson K., Huh C., Grubb A., Karlsson S., Abrahamson M. Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution. Comp Biochem Physiol B Biochem Mol Biol 1996, 114:303-311.
60. Song S., Meyer M., Turk T.R., Wilde B., Feldkamp T., Assert R., et al. Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine. Nephrol Dial Transplant 2009, 24:1157-1161.
61. Xu Y., Schnorrer P., Proietto A., Kowalski G., Febbraio M.A., Acha-Orbea H., et al. IL-10 controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression. J Immunol 2011, 186:3666-3673.
62. Qi Z., Whitt I., Mehta A., Jin J., Zhao M., Harris R.C., et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004, 286:F590-F596.
63. Zhao H.J., Wang S., Cheng H., Zhang M.Z., Takahashi T., Fogo A.B., et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006, 17:2664-2669.
64. Sharma K., McCue P., Dunn S.R. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003, 284:F1138-F1144.
65. Huang W., Gallois Y., Bouby N., Bruneval P., Heudes D., Belair M.F., et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A 2001, 98:13330-13334.
66. Nakagawa T., Sato W., Glushakova O., Heinig M., Clarke T., Campbell-Thompson M., et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007, 18:539-550.
67. Ito T., Tanimoto M., Yamada K., Kaneko S., Matsumoto M., Obayashi K., et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton) 2006, 11:29-35.
68. Zheng S., Noonan W.T., Metreveli N.S., Coventry S., Kralik P.M., Carlson E.C., et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 2004, 53:3248-3257.
69. da Costa Goncalves A.C., Tank J., Diedrich A., Hilzendeger A., Plehm R., Bader M., et al. Diabetic hypertensive leptin receptor-deficient db/db mice develop cardioregulatory autonomic dysfunction. Hypertension 2009, 53:387-392.
70. do Carmo J.M., da Silva A.A., Cai Z., Lin S., Dubinion J.H., Hall J.E. Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons. Hypertension 2011, 57:918-926.